Evolent Health (NYSE:EVH) Stock Price Passes Below 200 Day Moving Average – Should You Sell?

Posted by Stanley Muller on Aug 9th, 2026

Evolent Health, Inc (NYSE:EVH – Get Free Report)’s share price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $3.72 and traded as low as $3.61. Evolent Health shares last traded at $3.9580, with a volume of 5,080,277 shares trading hands.

More Evolent Health News

Here are the key news stories impacting Evolent Health this week:

Positive Sentiment: Evolent reported second-quarter adjusted earnings of $0.02 per share, compared with analysts’ expectation of a $0.01 loss and a $0.10 loss in the year-ago quarter. Evolent Health Tops Q2 Earnings and Revenue Estimates
Positive Sentiment: Quarterly revenue rose sharply year over year, with management emphasizing continued growth, improving profitability, and stronger cash flow. The earnings call also highlighted a bullish 2027 outlook, supporting the view that Evolent’s expansion is becoming more durable. Evolent Health Q2 2026 Earnings Call Highlights
Positive Sentiment: The company raised or reaffirmed full-year 2026 revenue guidance at approximately $2.6 billion to $2.7 billion, above the roughly $2.5 billion consensus estimate. That outlook gives investors greater confidence in Evolent’s growth trajectory. Evolent Announces Second Quarter 2026 Results
Neutral Sentiment: Despite the improved operating performance, Evolent remains unprofitable on a GAAP basis, with a negative net margin, and analysts still project a full-year loss. Execution against the new guidance will therefore remain important.
Negative Sentiment: The company continues to carry elevated leverage, including a debt-to-equity ratio above 2, which could limit financial flexibility if growth or cash-flow improvements fall short.

Wall Street Analysts Forecast Growth

EVH has been the subject of several research reports. Citigroup reiterated a “sell” rating and set a $6.75 price objective (up from $5.50) on shares of Evolent Health in a research note on Thursday, July 23rd. Needham & Company LLC upped their target price on Evolent Health from $4.00 to $5.00 and gave the company a “buy” rating in a research report on Thursday, May 7th. Truist Financial lowered Evolent Health from a “buy” rating to a “hold” rating and set a $7.00 target price for the company. in a research note on Tuesday, June 30th. Canaccord Genuity Group lifted their price target on Evolent Health from $6.00 to $7.00 and gave the stock a “buy” rating in a research report on Tuesday, July 21st. Finally, TD Cowen dropped their price target on Evolent Health from $8.00 to $5.00 and set a “buy” rating on the stock in a research note on Tuesday, July 28th. Eleven equities research analysts have rated the stock with a Buy rating, four have issued a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $6.16.

Check Out Our Latest Stock Report on Evolent Health

Evolent Health Stock Up 10.3%

The company has a current ratio of 1.32, a quick ratio of 1.32 and a debt-to-equity ratio of 2.46. The company has a market capitalization of $445.20 million, a PE ratio of -0.87 and a beta of 0.79. The business’s 50-day simple moving average is $4.75 and its 200-day simple moving average is $3.72.

Evolent Health (NYSE:EVH – Get Free Report) last released its quarterly earnings data on Thursday, August 6th. The technology company reported $0.02 EPS for the quarter, beating the consensus estimate of ($0.01) by $0.03. The business had revenue of $484.50 million for the quarter, compared to the consensus estimate of $597.70 million. Evolent Health had a negative net margin of 24.08% and a negative return on equity of 3.94%. The business’s revenue for the quarter was up 46.9% on a year-over-year basis. During the same period in the prior year, the firm earned ($0.10) EPS. As a group, equities research analysts anticipate that Evolent Health, Inc will post -0.16 EPS for the current fiscal year.

Institutional Investors Weigh In On Evolent Health

Several hedge funds have recently added to or reduced their stakes in the business. Royal Bank of Canada grew its position in Evolent Health by 51.6% during the 1st quarter. Royal Bank of Canada now owns 25,161 shares of the technology company’s stock worth $57,000 after purchasing an additional 8,563 shares during the period. Maverick Capital Ltd. boosted its stake in shares of Evolent Health by 1.3% in the first quarter. Maverick Capital Ltd. now owns 2,572,763 shares of the technology company’s stock worth $5,866,000 after buying an additional 32,833 shares during the last quarter. Sei Investments Co. boosted its stake in shares of Evolent Health by 50.8% in the first quarter. Sei Investments Co. now owns 302,281 shares of the technology company’s stock worth $689,000 after buying an additional 101,867 shares during the last quarter. State of Wyoming boosted its stake in shares of Evolent Health by 54.7% in the first quarter. State of Wyoming now owns 121,751 shares of the technology company’s stock worth $278,000 after buying an additional 43,061 shares during the last quarter. Finally, First Trust Advisors LP acquired a new stake in Evolent Health during the first quarter worth about $488,000.

About Evolent Health

(Get Free Report)

Evolent Health, Inc is a U.S.-based healthcare technology and services company that partners with health systems, physician organizations and health plans to design, build and operate value-based care programs. Headquartered in Arlington, Virginia, the company was founded in 2011 as a joint venture between TPG and the University of Pittsburgh Medical Center (UPMC). Evolent Health aims to help its clients transition from fee-for-service payment models to value-based care arrangements by leveraging its proprietary technology platforms and clinical expertise.

The company’s core offerings include care management solutions, population health analytics and clinical advisory services.